Teriparatide

Type: Keyphrase
Name: Teriparatide
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Radius Health Announces Presentations at the American Society for Bone and Mineral Research 2014 Annual Meeting

Meeting to Include New Responder Analysis of Effects of Abaloparatide on Bone Mineral Density in Postmenopausal Women With OsteoporosisCAMBRIDGE, Mass., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will present ... [Published Virtual Strategy Magazine - Aug 19 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

New protocols for diagnosis and treatment

Prof Douglas Veale, Consultant Rheumatologist, SVUHLong-term steroid use is an issue in osteoporosis and this will remain the case. The optimum length of a drug holiday for such treatments as bisphosphonates is unknown, Gary Culliton reports in his latest ... [Published Irish Medical Times - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Chronic CKD-MBDs: What the Endocrinologist Needs to Know

Coresh J, Astor BC, Greene T, Eknovan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.National Kidney Foundation. ... [Published General Medicine eJournal - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Eli Lilly 2nd-qtr sales takes hit from generics; net income falls 39%

US pharma major Eli Lilly (NYSE: LLY) reported second quarter 2014 revenues fell 17% to $4.935 billion, reflecting generic competition for Cymbalta (duloxetine) and Evista (raloxifene) in the USA.However, revenues still exceeded the Zacks Equity Research ... [Published Pharma Letter - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President

(GLOBE NEWSWIRE) -- . (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, ... [Published EMoneyDaily - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

New Findings on Postmenopausal Osteoporosis Reported by S.S. Maeda et al (An overview on the treatment of postmenopausal osteoporosis)

By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Metabolic Bone Diseases is the subject of a report. According to news reporting out of Sao Paulo, Brazil , by NewsRx editors, research stated, "Osteoporosis is a worldwide ... [Published 4 Traders - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Human medicines European public assessment report (EPAR): Forsteo, teriparatide, Revision: 15, Authorised

Entities: Forsteo, Teriparatide
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

New agent builds bone bigger, faster

CHICAGO – Abaloparatide, a synthetic analog of human parathyroid hormone–related peptide, displayed jaw-dropping superiority to teriparatide in boosting bone mineral density at multiple anatomic... ... [Published Ob.Gyn. News - Jul 18 2014]
First reported Jul 13 2014 - Updated Jul 13 2014 - 1 reports

Abstract and Introduction – Medscape

Abstract and IntroductionMedscapeObjectives To quantify incremental effects of applying different criteria to identify men who are candidates for drug treatment to prevent fracture and to examine the extent to which fracture probabilities vary across ... [Published ISCD - Jul 13 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 1 reports

MicroCHIPS develops contraceptive implant

18:10, Technology/Hi Tech & InnovationScientists are making drug development news with their investigations into ways that enable implantable devices to deliver drugs, cutting the wear and care of traditionally delivered pills and injections. Now a Lexington, ... [Published PhysOrg.com - Jul 07 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Critical Pharmaceuticals receives notice of allowance from USPTO for two hormone products

Critical Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application directed towards the company's CP024 intranasal growth hormone and CP046 intranasal teriparatide (parathyroid ... [Published PBR - News - Apr 09 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Sanford announces seed grant research funding winners

Six Sanford Health clinicians have been chosen to receive funding from the Sanford Seed Grant research fund, which was established in 2011 to grow and evolve unfunded research ideas.“By investing in our clinicians’ ideas, we’re investing in the quality ... [Published Argus Leader - Mar 21 2014]

Quotes

...us great confidence that Lilly is poised for growth in the years ahead," said John Lechleiter, Lilly's chairman president and chiefchief executive. "We have stayed the course with our innovation-based strategy, replenishing and advancing our pipeline. We remain firm in our commitment to sustain and accelerate a flow of important new medicines that make life better for people around the world" he added
According to the news editors, the research concluded: "Based on the knowledge on bone cells signaling, novel drugs were developed and are being assessed in clinical trials."
...Agarwal. "To develop novel therapies for these patients who have no approved treatments and to help push the science forward in these rare genetic diseases is something I am thrilled to be a part of."

More Content

All (16) | News (13) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Radius Health Announces Presentations at the Am... [Published Virtual Strategy Magazine - Aug 19 2014]
Radius Health Announces Presentations at the Am... [Published EMoneyDaily - Aug 19 2014]
New protocols for diagnosis and treatment [Published Irish Medical Times - Jul 31 2014]
Chronic CKD-MBDs: What the Endocrinologist Need... [Published General Medicine eJournal - Jul 29 2014]
Eli Lilly 2nd-qtr sales takes hit from generics... [Published Pharma Letter - Jul 25 2014]
New Findings on Postmenopausal Osteoporosis Rep... [Published 4 Traders - Jul 23 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 23 2014]
Ultragenyx Appoints Sunil Agarwal, M.D. as Chie... [Published EMoneyDaily - Jul 23 2014]
New agent builds bone bigger, faster [Published Ob.Gyn. News - Jul 18 2014]
Abstract and Introduction – Medscape [Published ISCD - Jul 13 2014]
MicroCHIPS develops contraceptive implant [Published PhysOrg.com - Jul 07 2014]
Critical Pharmaceuticals receives notice of all... [Published PBR - News - Apr 09 2014]
On the Move [Published Argus Leader - Mar 24 2014]
Sanford announces seed grant research funding w... [Published Argus Leader - Mar 21 2014]
Can Novel-Novel Combinations Work? Deals Of The... [Published The IN VIVO Blog - Feb 07 2014]
Combination treatment with strontium for the pr... [Published PharmCast - Jan 22 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 23 2014]
Critical Pharmaceuticals receives notice of all... [Published PBR - News - Apr 09 2014]
Critical Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application directed towards the company's CP024 intranasal growth hormone and CP046 intranasal teriparatide (parathyroid ...
Can Novel-Novel Combinations Work? Deals Of The... [Published The IN VIVO Blog - Feb 07 2014]
Merck & Co. Inc.’s Feb. 5 announcement that it is collaborating with three companies to test various combinations of its investigational oncology compound MK-3475 with their drugs highlights the extent to which the big pharma is committed to building ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.